Self-assembling nanoparticles and methods of making and using, exosome-encapsulated nanomaterials and uses

Abstract

The application discloses self-assembled nanoparticles, a preparation method and application thereof, and exosome-wrapped nanomaterials containing the self-assembled nanoparticles and application thereof, wherein the self-assembled nanoparticles comprise schisandrol and chlorogenic acid, and the schisandrol and the chlorogenic acid are mixed to form nanoparticles. The self-assembled nanoparticles are formed by self-assembly of schisandrol and chlorogenic acid, the self-assembled nanoparticles have excellent antioxidant performance, the self-assembled nanoparticles are wrapped by exosomes to form nanomaterials, and the nanomaterials can treat liver injury and promote formation of specific immune tolerance.

Description

Technical Field

[0001] This invention belongs to the technical field of self-assembled materials, specifically relating to a self-assembled nanoparticle, its preparation method and application, and nanomaterials containing self-assembled nanoparticles encapsulated in exosomes and their applications. Background Technology

[0002] In daily work and life, excessive drinking or improper diet can cause acute liver injury; acute liver injury can cause loss of appetite, abdominal pain and other symptoms, which seriously affect normal life.

[0003] Current treatments for acute liver injury primarily utilize Western medicine, such as antioxidants or anti-inflammatory drugs, to reduce oxidative stress in the liver and inhibit stem cell inflammation. However, these treatments often have significant side effects, including elevated liver enzyme levels, unilateral stasis jaundice, drug-induced fatty liver, and gastrointestinal bleeding.

[0004] While traditional Chinese medicine can alleviate and regulate liver function with minimal side effects, it cannot be directly used to treat acute liver injury because it works slowly and the symptoms of acute liver injury are urgent and obvious. Summary of the Invention

[0005] The purpose of this invention is to overcome the shortcomings of the prior art by providing a self-assembled nanoparticle, its preparation method and application, and a nanomaterial containing self-assembled nanoparticles encapsulated by exosomes and its application. The nanoparticles are formed by the self-assembly of schisandrol and chlorogenic acid. The self-assembled nanoparticles have excellent antioxidant properties. The self-assembled nanoparticles are encapsulated by exosomes to form nanomaterials. The nanomaterials can treat liver damage and promote the formation of specific immune tolerance.

[0006] To achieve the above objectives, the present invention provides a self-assembled nanoparticle comprising schisandrol and chlorogenic acid, wherein the schisandrol and chlorogenic acid are mixed to form the nanoparticle.

[0007] Furthermore, the mass ratio of schisandrol to chlorogenic acid is 1:0.5-1.5.

[0008] Furthermore, the particle size of the self-assembled nanoparticles is 80-90 nm.

[0009] This application also provides a method for preparing self-assembled nanoparticles, including:

[0010] Schisandrol and chlorogenic acid were mixed and added to anhydrous ethanol and ultrasonically dispersed to obtain the first mixture.

[0011] The first mixture was added dropwise to pure water and ultrasonically dispersed to obtain the second mixture;

[0012] Remove the anhydrous ethanol from the second mixture to obtain self-assembled nanoparticles.

[0013] This application also provides an application of self-assembled nanoparticles, as described above, for in vitro antioxidant purposes.

[0014] This application also provides an exosome-encapsulated nanomaterial, including exosomes and self-assembled nanoparticles encapsulated by the exosomes, wherein the self-assembled nanoparticles are the same as described above.

[0015] Furthermore, the mass ratio of the exosomes to the self-assembled nanoparticles is 1:90-110.

[0016] Furthermore, the particle size of the nanomaterial is 100-120 nm.

[0017] This application also provides an application of exosome-encapsulated nanomaterials, as described above, for the treatment of liver injury.

[0018] This application also provides an application of exosome-encapsulated nanomaterials, wherein the nanomaterials described above are used to promote the formation of specific immune tolerance.

[0019] The present invention has the following beneficial effects:

[0020] In this application, schisandrol and chlorogenic acid are mixed by ultrasound to self-assemble into uniformly dispersed nanoparticles. These self-assembled nanoparticles exhibit excellent multi-antioxidant properties against various free radicals in vitro. The self-assembled nanoparticles are then encapsulated by exosomes to form nanomaterials with uniform particle size. These exosome-encapsulated nanomaterials can effectively reduce liver tissue damage and necrosis, demonstrating a significant therapeutic effect on liver injury. Simultaneously, the exosome-encapsulated nanomaterials can effectively regulate inflammatory responses, positively impacting liver inflammation by inhibiting the expression of pro-inflammatory factors and promoting the production of anti-inflammatory factors, thereby promoting effective specific immune tolerance. Attached Figure Description

[0021] Figure 1 This is a transmission electron microscope image of the self-assembled nanoparticles in Example 1;

[0022] Figure 2 This is a Zeta potential diagram of the self-assembled nanoparticles in Example 1;

[0023] Figure 3 This is a schematic diagram illustrating the free radical scavenging ability of self-assembled nanoparticles at different concentrations in Example 2;

[0024] Figure 4 The electron spin resonance spectrum of the nanomaterial in Example 2;

[0025] Figure 5 This is a transmission electron microscope (TEM) image of the nanomaterials in Example 3;

[0026] Figure 6 The graph shows the serum ALT and AST results of mice in the blank control group, induction control group, and drug administration control group in Example 4; n=6-8; ***p<0.001, ****p<0.0001;

[0027] Figure 7 This is a schematic diagram showing the histopathological observation results of the blank control group, induction control group, and drug administration control group in Example 4. Figure 7 A is a typical H&E staining diagram; Figure 7 B represents the statistical results of the hepatocellular necrosis area; Figure 7 C is a typical image of TUNEL staining; Figure 7 D represents the statistical results of hepatocyte apoptosis; n=3-4; **p<0.01, ****p<0.0001, scale bar=100μm;

[0028] Figure 8 This is a schematic diagram of the detection of inflammatory factor levels in mouse serum by ELISA in Example 4; **p<0.01, ***p<0.001, ****p<0.0001;

[0029] Figure 9 The image shows the immunofluorescence staining patterns of CD86 (red), CD206 (red), F4 / 80 (green), and DAPI (blue) in Example 5.

[0030] Figure 10 The levels of inflammatory and anti-inflammatory factors in mouse liver were detected by qRT-PCR in Example 5; *p<0.05, **p<0.01, ***p<0.001;

[0031] Figure 11 Results and statistics for flow cytometry analysis; *p<0.05, **p<0.01, ***p<0.001. Detailed Implementation

[0032] Preferred embodiments of the invention will now be described in more detail with reference to the accompanying drawings. While preferred embodiments of the invention are shown in the drawings, it should be understood that the invention can be implemented in various forms and should not be limited to the embodiments set forth herein. Rather, these embodiments are provided so that the invention will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.

[0033] This application provides a method for preparing self-assembled nanoparticles, comprising:

[0034] S1: Schisandrin and chlorogenic acid are mixed and added to anhydrous ethanol and ultrasonically dispersed to obtain the first mixture; specifically, the mass ratio of schisandrin to chlorogenic acid is 1:0.5-1.5; the mass ratio of schisandrin to anhydrous ethanol is 1:0.5-1.5; and the ultrasonic time is 10-20 minutes.

[0035] S2: The first mixture is added dropwise to pure water and ultrasonically dispersed to obtain a second mixture; the mass ratio of schisandrol to pure water in the first mixture is 1:0.5-1.5; the ultrasonic time is 10-20 minutes.

[0036] S3: Remove anhydrous ethanol from the second mixture to obtain self-assembled nanoparticles. Specifically, the ethanol in the second mixture can be removed by rotary evaporation.

[0037] This application also provides self-assembled nanoparticles prepared by the above method, with a particle size of 80-90 nm, for use in vitro antioxidant purposes.

[0038] This application also provides an exosome-encapsulated nanomaterial, comprising exosomes and self-assembled nanoparticles as described above encapsulated by the exosomes. Specifically, the exosomes can be mesenchymal stem cell-derived exosomes or other exosomes existing in the art. In this application, the exosomes play two roles in the nanomaterial: First, exosomes facilitate the targeted aggregation of the nanomaterial to inflammatory sites. Second, the exosomes themselves possess anti-inflammatory and protective effects, and they have a synergistic therapeutic effect with the self-assembled nanoparticles.

[0039] In this application, the mass ratio of exosomes to self-assembled nanoparticles in the nanomaterial is 1:90-110, and the resulting nanomaterial has a particle size of 100-120 nm. It is used to treat liver injury and to promote the formation of specific immune tolerance.

[0040] Example 1: Self-assembled nanoparticles and their preparation method

[0041] This embodiment provides a method for preparing self-assembled nanoparticles, including:

[0042] S1: Mix 5 mg of schisandrol and 5 mg of chlorogenic acid and add them to 5 ml of anhydrous ethanol. Disperse the mixture by sonication for 15 minutes to obtain the first mixture.

[0043] S2: Slowly add the first mixture dropwise to 5ml of pure water and sonicate for 15 minutes to obtain the second mixture;

[0044] S3: Remove anhydrous ethanol from the second mixture using a rotary evaporator to obtain self-assembled nanoparticles (SAL-CA).

[0045] like Figure 1The image shown is a TEM image of the SAL-CA prepared in this embodiment. It can be seen that the self-assembled nanoparticles (SAL-CA) form uniformly dispersed nanoparticles with a particle size of about 80-90 nm. Figure 2 Zeta potential analysis of SAL-CA showed that the self-assembled nanoparticles (SAL-CA) had a Zeta potential of +10.45 mV, indicating that the self-assembled nanoparticles (SAL-CA) have good stability in aqueous media. These results demonstrate that the SAL-CA prepared in this embodiment possesses a uniformly dispersed nanostructure and good stability, which is beneficial for biomedical applications.

[0046] It should be noted that by changing the volume of pure water in step S2, this application can prepare a series of self-assembled nanoparticle solutions with different concentrations. Alternatively, this application can also prepare a series of self-assembled nanoparticles with different concentrations by dissolving the prepared self-assembled nanoparticles in different volumes of pure water.

[0047] Example 2: Application of self-assembled nanoparticles

[0048] Self-assembled nanoparticle solutions with concentrations of 50 μg / mL, 100 μg / mL, 200 μg / mL, 400 μg / mL, 600 μg / mL, and 800 μg / mL were prepared according to Example 1. It should be noted that preparing self-assembled nanoparticle solutions of different concentrations only requires changing the volume of pure water added in step S2; the concentration of the self-assembled nanoparticle solution prepared in Example 1 was 2000 μg / mL.

[0049] The scavenging rates of ABTS radicals by the self-assembled nanoparticle solutions of different concentrations prepared above were calculated, and the results are as follows: Figure 3 As shown in Figure A. The scavenging rate of DPPH free radicals by the self-assembled nanoparticle solutions of different concentrations prepared above was calculated, and the results are as follows. Figure 3 As shown in B. The effects of different concentrations of the self-assembled nanoparticle solutions prepared above on superoxide anions (O2) were calculated. - The elimination rate of free radicals, the results are as follows: Figure 3 As shown in C.

[0050] Combination Figure 3 It can be seen that the self-assembled nanoparticles (SAL-CA) can effectively scavenge ABTS and DPPH radicals in a concentration-dependent manner. Specifically, as the concentration of the self-assembled nanoparticles (SAL-CA) increased from 50 μg / mL to 800 μg / mL, the elimination rate of ABTS radicals rapidly increased from 12% to 86%.

[0051] Similarly, when the concentration of self-assembled nanoparticles (SAL-CA) reached 800 μg / mL, the scavenging rate of DPPH radicals also reached 87%, showing a clear concentration dependence.

[0052] Furthermore, self-assembled nanoparticles (SAL-CA) enhance the resistance of superoxide anions (O2). - The free radical scavenging effect was also good, with a scavenging rate of up to 45% at a concentration of 800 μg / mL. These results fully demonstrate that the self-assembled nanoparticles (SAL-CA) have excellent and rapid free radical scavenging ability.

[0053] To further verify the antioxidant properties of self-assembled nanoparticles (SAL-CA), this embodiment employed electron spin resonance (ESR) technology to obtain SAL-CA's ability to capture hydroxyl radicals (•OH), DPPH radicals, and superoxide anions (O2). - ESR spectra of free radical adducts, such as Figure 4 As shown.

[0054] like Figure 4 As shown in Figure A, the ESR signal peak of hydroxyl radicals (•OH) is significantly reduced in the presence of SAL-CA, which intuitively reflects the highly efficient scavenging ability of SAL-CA for •OH. Figure 4 As shown in Figure B, in the presence of SAL-CA, the O2 in the ESR spectrum - The peak intensity of the adduct also decreased accordingly, indicating that O2 - The adduct was effectively consumed. Similarly, as... Figure 4 As shown in Figure C, the ESR signal peak of DPPH also showed a significant decrease under the action of SAL-CA, further confirming the excellent scavenging ability of SAL-CA for DPPH•.

[0055] In summary, the self-assembled nanoparticles (SAL-CA) in this application exhibit in vitro resistance to various free radicals (such as O2). - (ABTS free radical, DPPH free radical, OH) can exhibit excellent multiple antioxidant properties and can be used for in vitro antioxidant activity.

[0056] Example 3: Preparation of nanomaterials encapsulated by exosomes

[0057] This embodiment provides an exosome-encapsulated nanomaterial, using mesenchymal stem cell-derived exosomes, specifically mesenchymal stem cell exosomes, as an example for illustration:

[0058] S1: Preparation of mesenchymal stem cell-derived exosomes (EVs):

[0059] S11: Human mesenchymal stem cells (hMSCs) were cultured in a suitable culture medium to promote the production of exosomes. The cultured cell culture medium was centrifuged at 500 g for 10 min to remove cell debris and larger particles, and the supernatant was then further purified by centrifugation at 12000 g for 20 min.

[0060] S12: Precipitate the exosomes by ultracentrifugation at 100,000 g for 70 min, carefully remove the precipitate and resuspend it in an appropriate buffer. For further purification, the resuspended exosomes were ultracentrifuged again at 100,000 g for 70 min, and the supernatant was collected to obtain purified exosomes.

[0061] S2: At 4°C, the purified EVs were mixed with the SAL-CA prepared in Example 1 at a ratio of 1:100 and stirred overnight to form nanomaterials encapsulated by mesenchymal stem cell exosomes, referred to as SAL-CA EVs in the following text and figures.

[0062] like Figure 5 As shown, transmission electron microscopy revealed the binding of SAL-CA and EVs in the nanomaterial. SAL-CA appeared as a relatively round nanoparticle with obvious exosome structures attached to its surface. The particle size of the nanomaterial was about 100-120 nm. Figure 5 This study confirms the effective binding of SAL-CA to EVs, laying the foundation for further research on the biological function and potential applications of the SAL-CA EVs complex.

[0063] Example 4: Exosome-encapsulated nanomaterials for the treatment of liver injury

[0064] Blank control group: Mice were not induced by APAP and were not given SAL-CA EVs. Figure 6 The first column is shown (in the attached figure, it is indicated by APAP- and SAL-CA EVs-).

[0065] Induction control group: Mice induced by APAP but not given SAL-CA EVs, such as... Figure 6 As shown in the second column (in the attached figure, it is indicated by APAP+ and SAL-CA EVs-).

[0066] Control group: Mice were induced with APAP and then administered SAL-CA EVs, such as Figure 6 The third column in the middle (in the attached figure, it is represented as APAP+ and SAL-CA EVs+)).

[0067] To investigate the therapeutic effect of SAL-CA EVs on acute liver injury, this study established an acetaminophen (APAP)-induced acute liver injury model in mice. ALT and AST are crucial biochemical indicators in liver function testing, primarily used to assess liver health and function. Serum ALT and AST levels significantly increase during the pathogenesis of acute liver injury. Therefore, serum ALT and AST levels were measured to assess the degree of liver damage. Figure 6 As shown, compared with the blank control group, the serum ALT and AST levels of mice in the induced control group were significantly increased, indicating that APAP successfully induced severe liver injury. Furthermore, compared with the induced control group, the ALT and AST levels of mice in the drug-treated control group were significantly decreased. This result indicates that SAL-CA EVs can effectively improve APAP-induced transaminase abnormalities in mice, thereby alleviating acute liver injury. Figure 6 In the given information, n = 6-8; ***p < 0.001, ****p < 0.0001.

[0068] To further investigate the protective effect of SAL-CA EVs against AILI, this embodiment included a histopathological evaluation. Liver tissue structure was observed using H&E staining, such as... Figure 7 As shown in Figure A, the liver tissue structure of the blank control group remained intact, with no obvious damage. In contrast, the induction control group showed obvious cell damage, with loose tissue structure, blurred cell outlines, and obvious areas of tissue necrosis, which are marked with dashed lines in the figure. The cell outlines in the drug-treated control group were relatively clear, and the area of ​​liver necrosis was significantly reduced. The corresponding liver necrosis areas of the blank control group, induction control group, and drug-treated control group are shown in Figure A. Figure 7 As shown in Figure B, this indicates that SAL-CA EVs can effectively reduce liver tissue damage and necrosis.

[0069] The number of apoptotic cells in the liver was quantitatively analyzed using TUNEL staining, such as... Figure 7 As shown in Figure C, green markers represent TUNEL-positive cells. The results showed no significant apoptotic cells in the blank control group. Conversely, the number of apoptotic cells was significantly increased in the induced control group. Compared to the induced control group, the number of apoptotic liver cells in the drug-treated control group was reduced. The TUNEL content of the blank control group, induced control group, and drug-treated control group is shown in Figure C. Figure 7 As shown in Figure D, this indicates that SAL-CA EVs have an inhibitory effect on APAP-induced apoptosis. Figure 7 In the above, n=3-4; **p<0.01, ****p<0.0001, scale bar=100 μm.

[0070] In summary, SAL-CA EVs demonstrated a significant protective effect in an APAP-induced acute liver injury model, effectively reducing cell apoptosis and thus exerting a therapeutic effect on liver injury.

[0071] To further evaluate the anti-inflammatory capacity of SAL-CA EVs in vivo, this embodiment used ELISA to detect inflammatory factors in the serum and liver of mice corresponding to the blank control group, induction control group, and drug-treated control group. The results are as follows: Figure 8 As shown, after administration of SAL-CA EVs, the abnormal increases in inflammatory factors such as IL-6, TNF-α, MCP-1, and IL-1β in mouse serum induced by APAP were significantly inhibited. Figure 8 **p < 0.01, ***p < 0.001, ****p < 0.0001. These results demonstrate that SAL-CA EVs can inhibit the inflammatory response in the mouse liver, thereby exerting a hepatoprotective effect.

[0072] Example 5: Exosome-encapsulated nanomaterials for promoting the formation of specific immune tolerance

[0073] Blank control group: Mice were not induced by APAP and were not given SAL-CA EVs. Figure 8 The first column is shown (in the attached figure, it is indicated by APAP- and SAL-CA EVs-).

[0074] Induction control group: Mice induced by APAP but not given SAL-CA EVs, such as... Figure 8 As shown in the second column (in the attached figure, it is indicated by APAP+ and SAL-CA EVs-).

[0075] Control group: Mice were induced with APAP and then administered SAL-CA EVs, such as Figure 8 The third column in the middle (in the attached figure, it is represented as APAP+ and SAL-CA EVs+)).

[0076] When AILI develops, the body can recognize pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). The recognition of these molecular patterns triggers a series of inflammatory responses, leading to the recruitment and activation of macrophages in the liver, promoting the M1-M2 macrophage phenotype transition, and thus initiating an inflammatory response. Therefore, in this embodiment, macrophage phenotypes were labeled using immunofluorescence staining with CD86 (a marker of M1 macrophages) and CD206 (a marker of M2 macrophages). Figure 9 As shown, in the induction control group, CD86 emitted bright fluorescence while CD206 emitted weak fluorescence, indicating that macrophages tended towards M1 polarization. In contrast, in the drug-treated control group, enhanced fluorescence signal of CD206 and weakened fluorescence signal of CD86 were observed, confirming that SAL-CA EVs promoted the conversion of macrophages from the M1 to the M2 phenotype. These results indicate that SAL-CA EVs can effectively improve inflammatory pathological states and liver function.

[0077] It should be noted that, Figure 9 DAPI (4',6-diamidinyl-2-phenylindole) is a fluorescent dye that binds strongly to DNA and is commonly used in fluorescence microscopy. It can pass through intact cell membranes and is used for staining both live and fixed cells. DAPI is primarily used to label cell nuclei, helping to determine cell morphology and location; it is shown in blue in the image. F4 / 80 is a highly glycosylated G protein-coupled receptor and a marker of mouse macrophages; it is shown in green in the image.

[0078] like Figure 10 The results showed that, at the mRNA level, the induction control group significantly increased the expression of Ccl2 and IL-1β compared with the blank control group, while the drug-treated control group reduced the levels of these pro-inflammatory cytokines in the liver.

[0079] Furthermore, the levels of CD206 and Arg-1, two anti-inflammatory factors, were significantly lower in the induction control group compared to the blank control group. In the treatment control group, the expression levels of these anti-inflammatory factors showed a significant rebound. These results indicate that SAL-CAEVs can effectively regulate the inflammatory response, potentially playing a positive role in improving liver inflammation by inhibiting the expression of pro-inflammatory factors and promoting the production of anti-inflammatory factors.

[0080] To study the in vivo immune effects, in this embodiment, spleen cells were extracted from mice corresponding to the blank control group, induction control group, and drug-treated control group after euthanasia, and immune cell analysis was performed using flow cytometry. Figure 11 A- Figure 11 As shown in Figure D, a shift in macrophage polarization from M1 to M2 was observed in the spleen of mice in the drug-treated control group. Quantitative analysis of M1 and M2 further confirmed this result.

[0081] Comparison of splenic dendritic cells (DCs) across groups revealed a lower proportion of mature DCs in the drug-treated control group. Figure 11 E and Figure 11 As shown in Figure F, this indicates that SAL-CA EVs can inhibit the maturation of DC cells, leaving them in an immature state of immune tolerance. These immune-tolerant DC cells are called tolerant DC cells (tDCs), and tolerant DC cells can suppress excessive immune activation in APAP mice.

[0082] SAL-CA EVs can also reduce T cell activation and proliferation by decreasing CD80 and CD86 expression and reducing T cell co-stimulatory signals, which helps control excessive immune responses, such as... Figure 11 G- Figure 11 As shown in H.

[0083] Furthermore, SAL-CA EVs can also inhibit the expression of Gr1 and NKP46, further regulating the immune response, such as Figure 11 I- Figure 11 As shown in J.

[0084] In summary, SAL-CA EVs can modulate the inflammatory immune response in APAP-treated mice, promote the formation of specific immune tolerance, and thus promote effective specific immune tolerance.

[0085] In this application, schisandrol and chlorogenic acid are mixed by ultrasound to self-assemble into uniformly dispersed nanoparticles. These self-assembled nanoparticles exhibit excellent multi-antioxidant properties against various free radicals in vitro. The self-assembled nanoparticles are then encapsulated by exosomes to form nanomaterials with uniform particle size. These exosome-encapsulated nanomaterials can effectively reduce liver tissue damage and necrosis, demonstrating a significant therapeutic effect on liver injury. Simultaneously, the exosome-encapsulated nanomaterials can effectively regulate inflammatory responses, positively impacting liver inflammation by inhibiting the expression of pro-inflammatory factors and promoting the production of anti-inflammatory factors, thereby promoting effective specific immune tolerance.

[0086] It is understood that the above embodiments only illustrate preferred embodiments of the present invention, and their descriptions are relatively specific and detailed, but they should not be construed as limiting the scope of the present invention. It should be noted that those skilled in the art can freely combine the above technical features without departing from the concept of the present invention, and can also make several modifications and improvements, all of which fall within the protection scope of the present invention. Therefore, all equivalent transformations and modifications made with respect to the scope of the claims of the present invention should fall within the scope of the claims of the present invention.

Claims

1. A self-assembling nanoparticle, characterized in that, The self-assembled nanoparticles comprise schisandrol and chlorogenic acid, and the mass ratio of the schisandrol and the chlorogenic acid is 1:0.5-1.

5.

2. The self-assembled nanoparticle of claim 1, wherein, The particle size of the self-assembled nanoparticles is 80-90 nm.

3. A method for preparing self-assembled nanoparticles, characterized by, The self-assembled nanoparticles comprise schisandrol and chlorogenic acid, and the mass ratio of the schisandrol and the chlorogenic acid is 1:0.5-1.

5. The particle size of the self-assembled nanoparticles is 80-90 nm. The self-assembled nanoparticles comprise schisandrol and chlorogenic acid, and the mass ratio of the schisandrol and the chlorogenic acid is 1:0.5-1.

5. The particle size of the self-assembled nanoparticles is 80-90 nm.

4. Use of self-assembling nanoparticles, characterized in that, The self-assembled nanoparticles comprise schisandrol and chlorogenic acid, and the mass ratio of the schisandrol and the chlorogenic acid is 1:0.5-1.

5.

5. An exosome-encapsulated nanomaterial, characterized in that, The particle size of the self-assembled nanoparticles is 80-90 nm.

6. The exosome-wrapped nanomaterial of claim 5, wherein, The self-assembled nanoparticles comprise schisandrol and chlorogenic acid, and the mass ratio of the schisandrol and the chlorogenic acid is 1:0.5-1.

5.

7. The exosome-wrapped nanomaterial of claim 5, wherein, The particle size of the self-assembled nanoparticles is 80-90 nm.

8. Use of an exosome-encapsulated nanomaterial, characterized in that, The self-assembled nanoparticles comprise schisandrol and chlorogenic acid, and the mass ratio of the schisandrol and the chlorogenic acid is 1:0.5-1.

5. The particle size of the self-assembled nanoparticles is 80-90 nm. The self-assembled nanoparticles comprise schisandrol and chlorogenic acid, and the mass ratio of the schisandrol and the chlorogenic acid is 1:0.5-1.

5. The particle size of the self-assembled nanoparticles is 80-90 nm. The self-assembled nanoparticles comprise schisandrol and chlorogenic acid, and the mass ratio of the schisandrol and the chlorogenic acid is 1:0.5-1.

5. The particle size of the self-assembled nanoparticles is 80-90 nm. The self-assembled nanoparticles comprise schisandrol and chlorogenic acid, and the mass ratio of the schisandrol and the chlorogenic acid is 1:0.5-1.

5. The particle size of the self-assembled nanoparticles is 80-90 nm. The self-assembled nanoparticles comprise schisandrol and chlorogenic acid, and the mass ratio of the schisandrol and the chlorogenic acid is 1:0.5-1.

5. The particle size of the self-assembled nanoparticles is 80-90 nm. The self-assembled nanoparticles comprise schisandrol and chlorogenic acid, and the mass ratio of the schisandrol and the chlorogenic acid is 1:0.5-1.

5. The particle size of the self-assembled nanoparticles is 80-90 nm. The self-assembled nanoparticles comprise schisandrol and chlorogenic acid, and the mass ratio of the schisandrol and

Images